Tweet
The North Carolina rally in front of Hagan’s office came off without a hitch due to the superb organizing efforts of Quang Pham, who writes:
We were only able to wear the ghost costumes and hold our signs in front of the office for about 15 minutes before security came and asked as if we had a permit, which we did not. Then we went inside to talk to Hagan’s staff, which wasn’t that useful since her staff was relatively new and was not knowledgeable about the issue. We did get some contacts though.
One news station did come to cover the event (News 14).
I spent my day with AMSA students on The Hill talking to Senate staffers about the need for affordable biologic drugs. They made me smile so much my face hurts. More coming soon.
6 Comments
Support this site!
Subscribe to the newsletter
Advertise on Firedoglake
Send
us your tips
Make us your homepage
About FDL Action
Kay Hagan is owned by the RTP Pharmas, like Glaxo et al. She thinks those 1,000 DrugCo employees are more important than the other millions of Carolinians…
How sad that Hagan (whose campaign I contributed to) has turned out to be
such a disappointment on health care.
And how encouraging that there are young people in medical school who
care enough to get involved and fight her.
Great to see. Thanks to the Med students!
God Bless These Children !
Jane – just now saw Eshoo has “responded” to you – heading over there now to read.
I was following that Kos diary yesterday. Slink was doing her best but there were some nasty comments towards FDL.
Yeah, Eshoo wrote a column over at Huff Po, I spoke of it a bit here in reporting on the action in Palo Alto. Eshoo specifically asserted that there are no evergreen provisions in her amendment, in fact they are prohibited. I’ve asked her staff to point me to the actual language that does this.
I’d like to add something, I’m confused about “data exclusivity” versus patents. These seem to be two different means for gaining revenue from the intellectual property associated with drug development. Can a small molecule or biologic medicine be outside of its data exclusivity period, yet still be covered by a patent? The cited wikipedia entry seems to say yes, that the exclusivity has to do with FDA regulatory data, not process/patent data.